Pain Management in Patients with Cancer

Introduction to Pain Management

• Cancer pain affects over 80% of patients with advanced cancer, significantly undermining quality of life, according to the American Society of Clinical Oncology and the World Health Organization (WHO) 1, 2, 3
• A multidisciplinary approach combining pharmacological and non-pharmacological treatments can yield effective pain control in up to 89% of advanced cancer patients, as reported by the European Society for Medical Oncology 4

Assessment and Classification of Pain

• The European Society for Medical Oncology recommends classifying pain based on intensity, with mild pain defined as ≤4/10, moderate pain as 5-6/10, and severe pain as ≥7/10 5
• Regular reassessment of pain intensity and treatment efficacy is crucial, and monitoring for opioid-related side effects is necessary to adjust treatment accordingly, as recommended by the American Society of Clinical Oncology 4, 1, 2, 6

Pharmacological Treatment of Pain

• Non-opioid analgesics, such as acetaminophen/paracetamol (500-1000 mg every 4-6 hours, max 4000 mg/day) and NSAIDs (e.g., ibuprofen 400-600 mg every 6-8 hours), are recommended as first-line treatment for pain management by the European Society for Medical Oncology 5
• Tramadol is recommended as a first-line treatment, with a starting dose of 50-100 mg every 4-6 hours (maximum 400 mg/day), and can be combined with acetaminophen for enhanced effect 5, 6
• Weak opioids plus non-opioids are recommended as first-line treatment for moderate pain, including tramadol and codeine or dihydrocodeine plus acetaminophen 5, 7
• Strong opioids, such as morphine, oxycodone, and hydromorphone, are recommended for first-line treatment of severe pain, with oral administration preferred, and transdermal fentanyl considered for stable pain in patients unable to swallow 4, 8
• The WHO analgesic ladder is a recommended approach for pain management:

7

Non-Pharmacological Treatment of Pain

• External beam radiotherapy is highly effective for painful bone metastases, with a single 8-Gy dose as the regimen of choice for localized bone pain, according to the American Society for Radiation Oncology and the World Health Organization (WHO) 7, 2, 9
• Whole Brain Radiation Therapy (WBRT) is standard for multiple brain metastases, with common schedules of 20 Gy in 5 fractions or 30 Gy in 10 fractions, which improves neurological symptoms and pain control 10, 9
• Stereotactic Radiosurgery (SRS) is preferred for 1-3 brain metastases, and may be used alone or with WBRT 10, 9
• Bisphosphonates or denosumab should be considered for patients with bone metastases to prevent skeletal complications and improve pain outcomes, as recommended by the National Comprehensive Cancer Network 1, 7
• Surgical intervention may be necessary for pathological fractures or high risk of fracture (>50% cortical involvement), and intramedullary nailing may be used for humeral lesions, as recommended by the American Academy of Orthopaedic Surgeons 9
• Vertebral augmentation procedures (vertebroplasty/kyphoplasty) may be considered for vertebral compression fractures causing pain, according to the American Academy of Orthopaedic Surgeons 9
• Heat therapy, spinal manipulation, acupressure, massage, and TENS (Transcutaneous Electrical Nerve Stimulation) may be effective for managing specific types of pain, such as acute low back pain, back pain with radiculopathy, acute musculoskeletal pain, postoperative pain, and acute musculoskeletal injuries, respectively 11
• Physical therapy is especially beneficial for musculoskeletal pain and lymphedema 12
• Psychological interventions are recommended for cancer pain management, as they can improve quality of life and reduce pain intensity 1

Special Considerations

• Patients with hypersensitivity to NSAIDs can tolerate acetaminophen in low to moderate doses (<1000 mg), although specific guidance is provided by the American College of Clinical Pharmacy 13
• Acetaminophen may cause liver toxicity, especially in high doses or with prolonged use, as noted by the National Comprehensive Cancer Network 14
• Selective COX-2 inhibitors, such as celecoxib, are generally well-tolerated by patients with hypersensitivity to NSAIDs, as recommended by the American Academy of Allergy, Asthma, and Immunology 13
• A challenge test with selective COX-2 inhibitors should be considered, according to the American Academy of Allergy, Asthma, and Immunology 13
• Antihistamines H1 in high doses (2-4 times the standard dose) may be considered as concomitant therapy, as suggested by the American Academy of Allergy, Asthma, and Immunology 13
• Patients may be able to use NSAIDs from a different structural class than the one causing the reaction, as noted by the American Academy of Allergy, Asthma, and Immunology 13
• A challenge test with an NSAID of a different chemical structure should be performed, according to the American Academy of Allergy, Asthma, and Immunology 13
• Liver function should be monitored with prolonged use of acetaminophen, as recommended by the National Comprehensive Cancer Network 14
• Patients should be monitored for signs of opioid addiction, abuse, and misuse, and each patient's risk for opioid addiction should be assessed prior to prescribing 15, 14
• Screening for risk of opioid misuse using validated tools is recommended 14
• Elderly or debilitated patients should receive reduced doses of opioids due to altered pharmacokinetics 1, 14
• Patients with advanced liver disease should have their acetaminophen dosage reduced 7
• Alternatives to NSAIDs should be considered in patients with renal impairment 7